Ametov, S.-T
Activation of GLP-1R leads to an increase in intracellular cAMP and/or calcium, triggering signaling pathways including protein kinase A (PKA), exchange proteins directly activated by cAMP (Epac-2), phospholipase C (PLC), and extracellular signal-regulated kinase 1 and 2 (ERK1/2), thereby mediating effects on glycemic regulation, immune process, and inflammation
Injectable tirzepatide remains the most common form, but alternatives are entering the market
2024;doi:10.1001/jamainternmed.2024.4369
Current 2026 approved GLP-1 RA medications include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
The potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing [abstract]